Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 ГБОУ ВПО Ставропольский государственный медицинский университет Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310. 2 Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер- Шева.
Список исп. литературыСкрыть список 1. Cornett EM, Novitch M, Kaye AD, Kata V, Kaye AM. (2017). Medication-induced tardive dyskinesia: a review and update. Ochsner Journal. 2017;17(2):162-174. 2. Kulkarni SK, Naidu PS. Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives. Drugs Today (Barc). 2003;39(1):19-49. DOI: 10.1358/dot.2003.39.1.799430 3. Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y). 2013;3:pii: tre-03-161-4138-1. DOI: 10.7916/D88P5Z71 4. Thelma B, Srivastava V, Tiwari AK. Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics. Pharmacogenomics. 2008;9(9):1285–1306. DOI: 10.2217/14622416.9.9.1285 5. Muller DJ, Chowdhury NI, Zai CC. The pharmacogenetics of antipsychotic-induced adverse events. Curr Opin Psychiatry. 2013;26(2):144–150. DOI: 10.1097/YCO.0b013e32835dc9da 6. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge university press; 2013. 7. Ito H, Takano H, Takahashi H, Arakawa R, Miyoshi M, Kodaka F, Okumura M, Otsuka T, Suhara T. Effects of the antipsychotic risperidone on dopamine synthesis in human brain measured by positron emission tomography with L-[beta-11C]DOPA: a stabilizing effect for dopaminergic neurotransmission? J Neurosci. 2009;29(43):13730–13734. DOI: 10.1523/JNEUROSCI.4172-09.2009 8. Rana AQ, Chaudry ZM, Blanchet PJ. New and emerging treatments for symptomatic tardive dyskinesia. Drug Des Devel Ther. 2013;7:1329-40.DOI: 10.2147/DDDT.S32328 9. Malik P, Andersen MB, Peacock L. The effects of dopamine D3 agonists and antagonists in a nonhuman primate model of tardive dyskinesia. Pharmacol Biochem Behav. 2004;78(4):805- 810. DOI: 10.1016/j.pbb.2004.05.019 10. Zai CC, Tiwari AK, Basile V, De Luca V, Müller DJ, King N, Voineskos AN, Remington G, Meltzer HY, Lieberman JA et al. Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients. Pharmacogenomics J. 2009;9(3):168-174.DOI: 10.1038/tpj.2009.2 11. Wilbur R, Kulik FA, Kulik AV. Noradrenergic effects in tardive dyskinesia, akathisia and pseudoparkinsonism via the limbic system and basal ganglia. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(6):849-864. DOI: 10.1016/0278-5846(88)90081-4 12. Kulkarni SK, Naidu PS. Tardive dyskinesia: An update. Drugs Today (Barc). 2001;37(2):97-119. DOI: 10.1358/dot.2001.37.2.834327. 13. Jeste DV, Linnoila M, Fordis CM, Phelps BH, Wagner RL, Wyatt RJ. Enzyme studies in tardive dyskinesia. III. Noradrenergic hyperactivity in a subgroup of dyskinetic patients. J Clin Psychopharmacol. 1982;2(5):318-320. 14. Jeste DV, Doongaji DR, Linnoila M. Elevated cerebrospinal fluid noradrenaline in tardive dyskinesia. Br J Psychiatry. 1984;144:177-180. DOI: 10.1192/bjp.144.2.177. 15. Casey DE. Tardive dyskinesia: nondopaminergic treatment approaches. Psychopharmacology Suppl. 1985;2:137-144. DOI: 10.1007/978-3-642-70140-5_18. 16. Kozell L, Sandyk R, Wagner GC, Fisher H. The effects of L-tryptophan on haloperidol-induced movement disorder in the rat. Life Sci. 1987;41 (14):1739-1744. DOI: 10.1016/0024-3205(87)90602-3. 17. Naidu PS, Kulkarni SK. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements. Eur J Pharmacol. 2001;428(1):81-86. DOI: 10.1016/s0014-2999(01)01284-5. 18. Obaid A, Haleem DJ, Saify ZS, Kamil N, Obaid R, Ahmed SW. Effects of tryptophan and valine administration on behavioral pharmacology of haloperidol. Pak J Pharm Sci. 2005;18(2):23-28. 19. Haleem DJ, Samad N, Haleem MA. Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats. Pharmacol Biochem Behav. 2007;87(1):115-121. DOI: 10.1016/j.pbb.2007.04.007. 20. Basile VS, Masellis M, Badri F, Paterson AD, Meltzer HY, Lieberman JA, Potkin SG, Macciardi F, Kennedy JL. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology. 1999;211:17- 27. DOI: 10.1016/S0893-133X(98) 00114-6 21. Al-Janabi I, Arranz MJ, Blakemore AF, Saiz PA, Susce MT, Glaser PA, Clark D, de Leon J. Association study of serotonergic gene variants with antipsychotic-induced adverse reactions. Psychiatr Genet. 2009;19(6):305-311. DOI: 10.1097/YPG.0b013e3283328dcd. 22. Müller DJ, Schulze TG, Knapp M, Held T, Krauss H, Weber T, Ahle G, Maroldt A, Alfter D, Maier W, Nöthen MM, Rietschel M. Familial occurrence of tardive dyskinesia. Acta Psychiatr Scand. 2001; 104(5):375-379. DOI: 10.1034/j.1600-0447.2001.00401.x 23. Ivanova SA, Loonen AJ, Bakker PR, Freidin MB, Ter Woerds NJ, Al Hadithy AF, Semke AV, Fedorenko OY, Brouwers JR, Bokhan NJ, van Os J, van Harten PN, Wilffert B. Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations. SAGE Open Med. 2016;4:2050312116643673. DOI: 10.1177/2050312116643673. 24. Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry. 2000;61(Suppl 3):16-21. 25. Hayashi T, Yokota N, Takahashi T, Tawara Y, Nishikawa T, Yano T, Furutani M, Fujikawa T, Horiguchi J, Yamawaki S. Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 1997;12(4):199-205. DOI: 10.1097/00004850-199707000-00003 26. Wynchank D, Berk M. Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double-blind randomised parallel group placebo-controlled trial. Hum Psychopharmacol. 2003;18(4):271-275. DOI: 10.1002/hup.476. 27. Shireen E. Experimental treatment of antipsychotic-induced movement disorders. J Exp Pharmacol. 2016;8:1-10. DOI: 10.2147/JEP.S63553. 28. Aleem A, Kulkarni A, Yeragani VK. Dexamethasone suppression test, schizophrenia and movement disorder. Acta Psychiatr Scand. 1988;78(6):689-694. DOI: 10.1111/j.1600-0447.1988.tb06405.x. 29. Sandyk R. Dexamethasone suppression test nonsuppression and tardive dyskinesia. Acta Psychiatr Scand. 1989;80(1):108-109. DOI: 10.1111/j.1600-0447.1989.tb01309.x. 30. Sandyk R. Melanocyte-stimulating hormone and persistent tardive dyskinesia: a hypothesis. Int J Neurosci. 1990;51(1-2):45-52. DOI: 10.3109 /00207459009000507. 31. Sun CH, Zheng W, Yang XH, Cai DB, Ng CH, Ungvari GS, Li HY, Wu YJ, Ning YP, Xiang YT. Adjunctive Melatonin for Tardive Dyskinesia in Patients with Schizophrenia: A Meta-Analysis. Shanghai Arch Psychiatry. 2017;29(3):129-136. DOI: 10.11919/j.issn.1002-0829.217046. 32. Rothschild AJ. Challenges in the treatment of depression with psychotic features. Biol Psychiatry. 2003;53(8):680-690. doi: 10.1016/s0006-3223(02)01747-x. 33. Benecke R, Conrad B, Klingelhöfer J. Successful treatment of tardive and spontaneous dyskinesias with corticosteroids. Eur Neurol. 1988;28(3):146-149. DOI: 10.1159/000116252. 34. van Zessen R, Phillips JL, Budygin EA, Stuber GD. Activation of VTA GABA neurons disrupts reward consumption. Neuron. 2012;73(6):1184-1194. DOI: 10.1016/j.neuron.2012.02.016 35. Tamminga CA, Crayton JW, Chase TN. Improvement in tardive dyskinesia after muscimol therapy. Arch Gen Psychiatry. 1979;36(5):595-598. DOI: 10.1001/archpsyc.1979.01780050105013 36. Clayton AH. Antidepressant-induced tardive dyskinesia: review and case report. Psychopharmacol Bull. 1995;31(2):259- 264. 37. Ragheb MM, Goldberg RJ. Tardive dyskinesia in geriatric patients. Aging Health. 2006;2(5):833–849.DOI: 10.1016/j.cger.2006.06.008 38. Teo JT, Edwards MJ, Bhatia K. Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord. 2012;27(10):1205–1215. DOI: 10.1002/mds.25107 39. Grimm JW, Chapman MA, Zahm DS, See RE. Decreased choline acetyl-transferase immunoreactivity in discrete striatal subregions following chronic haloperidol in rats. Synapse. 2001;39(1):51–57. 40. Wonodi I, Adami HM, Cassady SL, Sherr JD, Avila MT, Thaker GK. Ethnicity and the course of tardive dyskinesia in outpatients presenting to the motor disorders clinic at the Maryland psychiatric research center. J Clin Psychopharmacol. 2004;24(6):592- 598.DOI: 10.1097/01.jcp.0000144888. 43449.54 41. Sandyk R. Tardive dyskinesia: a role for the endogenous opioid system. Med Hypotheses. 1986;19(1):71-74. DOI: 10.1016/0306-9877(86)90138-6. 42. Carlson KR. A syndrome resembling tardive dyskinesia which results from chronic methadone treatment. Psychopharmacol Bull. 1978;14(4):76-77. 43. Gaspari J, Swift R, Kleber H, Riordan C, Santangelo S. Prevalence of movement disorder in a methadone-maintained population. J Nerv Ment Dis. 1985;173(6):373-376. DOI: 10.1097/00005053-198506000-00008 44. Berg D, Becker G, Naumann M, Reiners K. Morphine in tardive and idiopathic dystonia (short communication). J Neural Transm (Vienna). 2001;108(8-9):1035-1041. DOI: 10.1007/s007020170022. 45. Sandyk R. The endogenous opioid system in neurological disorders of the basal ganglia. Life Sci. 1985;37(18):1655-1663. DOI: 10.1016/0024-3205(85)90292-9 46. Carlson KR, Eibergen RD. Susceptibility to amphetamine-elicited dyskinesias following chronic methadone treatment in monkeys. Ann N Y Acad Sci. 1976;281:336-49. DOI: 10.1111/j.1749-6632.1976.tb27944.x. 47. Sandyk R. Neuroleptic-opioid interaction: relevance to tardive dyskinesia. Int J Neurosci. 1986;30(1-2):33-36. DOI: 10.3109/00207458608985652. 48. Meredith GE, De Souza IE, Hyde TM, Tipper G, Wong ML, Egan MF. Persistent alterations in dendrites, spines, and dynorphinergic synapses in the nucleus accumbens shell of rats with neuroleptic-induced dyskinesias. J Neurosci. 2000;20(20):7798-7806. DOI: 10.1523/JNEUROSCI.20-20-07798.2000. 49. McCormick SE, Stoessl AJ. Blockade of nigral and pallidal opioid receptors suppresses vacuous chewing movements in a rodent model of tardive dyskinesia. Neuroscience. 2002;112(4):851-859. doi: 10.1016/s0306-4522(02) 00127-6. 50. Ohmori O, Shinkai T, Hori H, Kojima H, Nakamura J. Polymorphisms of mu and delta opioid receptor genes and tardive dyskinesia in patients with schizophrenia. Schizophr Res. 2001;52(1-2):137-138. DOI: 10.1016/s0920-9964(00)00188-2. 51. Tan EC, Chong SA, Mahendran R, Tan CH, Teo YY. Mu opioid receptor gene polymorphism and neuroleptic-induced tardive dyskinesia in patients with schizophrenia. Schizophr Res. 2003;65(1):61-63. DOI: 10.1016/s0920-9964(02)00491-7. 52. Walters A, Hening W, Chokroverty S, Fahn S. Opioid responsiveness in patients with neuroleptic-induced akathisia. Mov Disord. 1986;1(2):119-127. DOI: 10.1002/mds.870010206. 53. Walters AS, Hening A. Opioids a better treatment for acute than tardive akathisia: possible role for the endogenous opiate system in neuroleptic-induced akathisia. Med Hypotheses. 1989;28(1):1-2. DOI: 10.1016/0306-9877(89)90145-x. 54. Wonodi I, Adami H, Sherr J, Avila M, Elliot HL, Thaker GK. Naltrexone treatment of tardive dyskinesia in patients with schizophrenia. J Clin Psychopharmacol. 2004;24(4):441-445. DOI: 10.1097/01.jcp.0000132440.27854.44 55. Ferrer B, Asbrock N, Kathuria S, Piomelli D, Giuffrida A. Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. Eur J Neurosci. 2003;18(6):1607-1614. DOI: 10.1046/j.1460-9568.2003.02896.x 56. Lian J, Deng С. The effects of antipsychotics on the density of cannabinoid receptors in selected brain regions of male and female adolescent juvenile rats. Psychiatry Res. 2018;266:317-322. DOI: 10.1016/j.psychres.2018.03.030. 57. Potvin S, Kouassi E, Lipp O, Bouchard RH, Roy MA, Demers MF, Gendron A, Astarita G, Piomelli D, Stip E. Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. J Psychopharmacol. 2008;22(3):262-269. DOI: 10.1177/0269881107083816. 58. Urigüen L, García-Fuster MJ, Callado LF, Morentin B, La Harpe R, Casadó V, Lluis C, Franco R, García-Sevilla JA, Meana JJ. Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. Psychopharmacology (Berl). 2009;206(2):313-324. DOI: 10.1007/s00213-009-1608-2. 59. Ranieri R, Laezza C, Bifulco M, Marasco D, Malfitano AM. Endocannabinoid System in Neurological Disorders. Recent Pat CNS Drug Discov. 2016;10(2):90-112. DOI: 10.2174/1574889810999160719105433 60. Müller-Vahl KR, Bindila L, Lutz B, Musshoff F, Skripuletz T, Baumgaertel C, Sühs KW. Cerebrospinal fluid endocannabinoid levels in Gilles de la Tourette syndrome. Neuropsychopharmacology. 2020;45(8):1323-1329. DOI: 10.1038/s41386-020-0671-6. 61. Kluger B, Triolo P, Jones W, Jankovic J. The therapeutic potential of cannabinoids for movement disorders. Mov Disord. 2015;30(3):313-327. DOI: 10.1002/mds.26142. 62. Kanaan AS, Jakubovski E, Müller-Vahl K. Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols. Brain Sci. 2017;7(5):47. DOI: 10.3390/brainsci7050047. 63. Antonazzo M, Botta M, Bengoetxea H, Ruiz-Ortega JA, Morera-Herreras T. Therapeutic potential of cannabinoids as neuroprotective agents for damaged cells conducing to movement disorders. Int Rev Neurobiol. 2019;146:229-257. DOI: 10.1016/bs.irn.2019.06.012. 64. Tiwari AK, Zai CC, Likhodi O, Voineskos AN, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Müller DJ, Kennedy JL. Association study of cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia. Pharmacogenomics J. 2012;12(3):260-266. DOI: 10.1038/tpj.2010.93. 65. Röpke J, Busanello A, Leal CQ, Reis EM, de Freitas CM, Villarinho JG, Figueira FH, Mello CF, Ferreira J, Fachinetto R. Anandamide attenuates haloperidol-induced vacuous chewing movements in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2014;54:195-199. DOI: 10.1016/j. pnpbp.2014.04.006 66. Sonego AB, Prado DS, Vale GT, Sepulveda-Diaz JE, Cunha TM, Tirapelli CR, Del Bel EA, Raisman-Vozari R, Guimarães FS. Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors. Brain Behav Immun. 2018;74:241-251. DOI: 10.1016/j.bbi.2018.09.014. 67. Moss DE, McMaster SB, Rogers J. Tetrahydrocannabinol potentiates reserpine-induced hypokinesia. Pharmacol Biochem Behav. 1981;15(5):779-783. DOI: 10.1016/0091-3057(81)90022-8. 68. Turčin A, Dolžan V, Porcelli S, Serretti A, Plesničar BK. Adenosine Hypothesis of Antipsychotic Drugs Revisited: Pharmacogenomics Variation in Nonacute Schizophrenia. OMICS. 2016;20(5):283-289. DOI: 10.1089/omi. 2016.0003. 69. Ivanova SA, Al Hadithy AF, Brazovskaya N, Semke A, Wilffert B, Fedorenko O, Brouwers JJ, Loonen AM. No involvement of the adenosine A2A receptor in tardive dyskinesia in Russian psychiatric inpatients from Siberia. Hum Psychopharmacol. 2012;27(3):334-337. DOI: 10.1002/hup.2226. 70. de Oliveira PA, Dalton JR, López-Cano M, Ricarte A, Morató X, Matheus FC, Cunha AS, Müller CE, Takahashi RN, Fernández-Dueñas V, Giraldo J, Prediger RD, Ciruela F. Angiotensin II type 1/adenosine A 2A receptor oligomers: a novel target for tardive dyskinesia. Sci Rep. 2017;7(1):1857. DOI: 10.1038/s41598-017-02037-z. 71. Hong CJ, Liu HC, Liu TY, Liao DL, Tsai SJ. Association studies of the adenosine A2a receptor (1976T > C) genetic polymorphism in Parkinson's disease and schizophrenia. J Neural Transm (Vienna). 2005;112(11): 1503-1510. DOI: 10.1007/s00702-005-0286-4. 72. Parsons B, Togasaki DM, Kassir S, Przedborski S. Neuroleptics up-regulate adenosine A2a receptors in rat striatum: implications for the mechanism and the treatment of tardive dyskinesia. J Neurochem. 1995;65(5):2057-2064. DOI: 10.1046/j.1471-4159.1995.65052057.x. 73. Bishnoi M, Chopra K, Kulkarni SK. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes. Eur J Pharmacol. 2006;552(1-3):55-66. DOI: 10.1016/j.ejphar.2006.09.010. 74. Bishnoi M, Chopra K, Kulkarni SK. Theophylline, adenosine receptor antagonist prevents behavioral, biochemical and neurochemical changes associated with an animal model of tardive dyskinesia. Pharmacol Rep. 2007;59(2):181-191. 75. Sasaki H, Hashimoto K, Inada T, Fukui S, Iyo M. Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol. Eur J Pharmacol. 1995;282(1-3):71-76. DOI: 10.1016/0014-2999(95)00278-s. 76. Sasaki H, Hashimoto K, Maeda Y, Inada T, Kitao Y, Fukui S, Iyo M. Rolipram, a selective c-AMP phosphodiesterase inhibitor suppresses oro-facial dyskinetic movements in rats. Life Sci. 1995;56(25):PL443-447. DOI: 10.1016/0024-3205(95)00218-u. 77. Bishnoi M, Chopra K, Kulkarni SK. Protective effect of adenosine reuptake inhibitors in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes. Pharmacology. 2007;79(3):171-183. DOI: 10.1159/000100924. 78. Банщиков ВМ, Невзорова ТА. Психиатрия. Издательство “Медицина”, 1969. - 344 с. 79. Harvey BH, Nel A. Role of aging and striatal nitric oxide synthase activity in an animal model of tardive dyskinesia. Brain Res Bull. 2003 30;61(4):407-416. DOI: 10.1016/s0361-9230(03)00143-6. 80. Nel A, Harvey BH. Haloperidol-induced dyskinesia is associated with striatal NO synthase suppression: reversal with olanzapine. Behav Pharmacol. 2003;14(3):251-255. DOI: 10.1097/00008877-200305000-00010. 81. Wang YC, Liou YJ, Liao DL, Bai YM, Lin CC, Yu SC, Chen JY. Association analysis of a neural nitric oxide synthase gene polymorphism and antipsychotics-induced tardive dyskinesia in Chinese schizophrenic patients. J Neural Transm (Vienna). 2004;111(5):623-629. DOI: 10.1007/s00702- 004-0118-y. 82. Shinkai T, Ohmori O, Matsumoto C, Hori H, Kennedy JL, Nakamura J. Genetic association analysis of neuronal nitric oxide synthase gene polymorphism with tardive dyskinesia. Neuromolecular Med. 2004;5(2):163-170. DOI: 10.1385/NMM:5:2:163. 83. Liou YJ, Lai IC, Lin MW, Bai YM, Lin CC, Liao DL, Chen JY, Lin CY, Wang YC. Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and tardive dyskinesia in patients with schizophrenia. Pharmacogenet Genomics. 2006;16(3):151-157. DOI: 10.1097/01.fpc.0000184958.05775.66. 84. Bester AM, Harvey BH. Early suppression of striatal cyclic GMP may predetermine the induction and severity of chronic haloperidol-induced vacuous chewing movements. Metab Brain Dis. 2000;15(4):275-285. DOI: 10.1023/a:1011171124603. 85. Bishnoi M, Chopra K, Kulkarni SK. Co-administration of nitric oxide (NO) donors prevents haloperidol-induced orofacial dyskinesia, oxidative damage and change in striatal dopamine levels. Pharmacol Biochem Behav. 2009;91(3):423-429. DOI: 10.1016/j.pbb.2008.08.021. 86. Naidu PS, Kulkarni SK. Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide. Behav Pharmacol. 2001;12(3):209-216. DOI: 10.1097/00008877-200105000-00006. 87. Lau YS, Petroske E, Meredith GE, Wang JQ. Elevated neuronal nitric oxide synthase expression in chronic haloperidol-treated rats. Neuropharmacology. 2003;45(7):986-994. DOI: 10.1016/s0028-3908(03)00314-9. 88. Gillman MA, Sandyk R. Tardive dyskinesia and glucose metabolism. Arch Gen Psychiatry. 1986;43(2):192-193. DOI: 10.1001/archpsyc.1986. 01800020102022. 89. Grover S, Kumar P, Singh K, Vikram V, Budhiraja RD. Possible beneficial effect of peroxisome proliferator-activated receptor (PPAR)--α and γ agonist against a rat model of oral dyskinesia. Pharmacol Biochem Behav. 2013;111:17-23. DOI: 10.1016/j.pbb.2013.08.001. 90. Wang SY, Wu SL, Chen TC, Chuang CS. Antidiabetic Agents for Treatment of Parkinson's Disease: A Meta-Analysis. Int J Environ Res Public Health. 2020;17(13):E4805. DOI: 10.3390/ijerph17134805. 91. Foltynie T, Athauda D. Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: Rationale and clinical experience. Prog Brain Res. 2020;252:493-523. DOI: 10.1016/bs.pbr.2019.10.008. 92. Siskind D, Hahn M, Correll CU, Fink-Jensen A, Russell AW, Bak N, Broberg BV, Larsen J, Ishøy PL, Vilsbøll T, Knop FK, Kisely S, Ebdrup BH. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis. Diabetes Obes Metab. 2019;21(2):293-302. DOI: 10.1111/dom.13522. 93. Jiang WL, Cai DB, Yin F, Zhang L, Zhao XW, He J, Ng CH, Ungvari GS, Sim K, Hu ML, Zheng W, Xiang YT. Adjunctive metformin for antipsychotic-induced dyslipidemia: a meta-analysis of randomized, double-blind, placebo-controlled trials. Transl Psychiatry. 2020;10(1):117. doi: 10.1038/s41398- 020-0785-y. 94. Iranpour N, Zandifar A, Farokhnia M, Goguol A, Yekehtaz H, Khodaie-Ardakani MR, Salehi B, Esalatmanesh S, Zeionoddini A, Mohammadinejad P, Zeinoddini A, Akhondzadeh S. The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial. Hum Psychopharmacol. 2016;31(2):103-112. DOI: 10.1002/hup.2517 95. Mouret J, Khomais M, Lemoine P, Sebert P. Low doses of insulin as a treatment of tardive dyskinesia: conjuncture or conjecture? Eur Neurol. 1991;31(4):199-203. DOI: 10.1159/000116678. 96. Uzunova V, Sampson L, Uzunov DP. Relevance of endogenous 3alpha-reduced neurosteroids to depression and antidepressant action. Psychopharmacology (Berl). 2006;186(3):351-361. doi: 10.1007/s00213-005-0201-6. 97. Sánchez P, Torres JM, Vílchez P, Del Moral RG, Ortega E. Effects of sulpiride on prolactin and mRNA levels of steroid 5alpha-reductase isozymes in adult rat brain. Neurochem Res. 2008;33(5):820-825. DOI: 10.1007/s11064-007-9512-9. 98. Bogus K, Pałasz A, Suszka-Świtek A, Worthington JJ, Krzystanek M, Wiaderkiewicz R. Chronic Antipsychotic Treatment Modulates Aromatase (CYP19A1) Expression in the Male Rat Brain. J Mol Neurosci. 2019;68(2):311-317. DOI: 10.1007/s12031-019-01307-x. 99. Bishnoi M, Chopra K, Kulkarni SK. Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid. Prog Neuropsycho- pharmacol Biol Psychiatry. 2008;32(2):451-461. 100. Bishnoi M, Chopra K, Kulkarni SK. Modulatory effect of neurosteroids in haloperidol-induced vacuous chewing movements and related behaviors. Psychopharmacology (Berl). 2008;196(2):243-254. doi: 10.1007/s00213-007-0956-z. 101. Ivanova SA, Geers LM, Al Hadithy AF, Pechlivanoglou P, Semke AV, Vyalova NM, Rudikov EV, Fedorenko OY, Wilffert B, Bokhan NA, Brouwers JJ, Loonen AM. Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry. 2014;50:172-177. DOI: 10.1016/j.pnpbp.2013.12.015 102. Glazer WM, Naftolin F, Moore DC, Bowers MB, MacLusky NJ. The relationship of circulating estradiol to tardive dyskinesia in men and postmenopausal women. Psychoneuroendocrinology. 1983;8(4):429-434. DOI: 10.1016/0306-4530(83)90022-7. 103. Bédard PJ, Boucher R, Daigle M, Paolo TD. Similar effect of estradiol and haloperidol on experimental tardive dyskinesia in monkeys. Psychoneuroendocrinology. 1984;9(4):375-379. DOI: 10.1016/0306-4530(84)90044-1. 104. Thakur KS, Prakash A, Bisht R, Bansal PK. Beneficial effect of candesartan and lisinopril against haloperidol-induced tardive dyskinesia in rat. J Renin Angiotensin Aldosterone Syst. 2015;16(4):917-929. DOI: 10.1177/ 1470320313515038. 105. Wang X, Zhu Y, Wang S, Wang Z, Sun H, He Y, Yao W. Effects of eplerenone on cerebral aldosterone levels and brain lesions in spontaneously hypertensive rats. Clin Exp Hypertens. 2020;42(6):531-538. doi: 10.1080/10641963.2020.1723615. 106. Vartanian KZ, Karimova MK. Experience using veroshpiron in the combined therapy of parkinsonism. Zh Nevropatol Psikhiatr Im S S Korsakova. 1988;88(12):14-18. 107. Karimova MK, Vartanian KZ, Petelin LS, Kubatiev AA. Effect of veroshpiron on hormone level in patients with Parkinson's disease. Klin Med (Mosk). 1994;72(4):36-39. 108. Teive HG, Munhoz RP, Werneck LC. Worsening of motor symptoms and gynecomastia during spironolactone treatment in a patient with Parkinson's disease and congestive heart failure. Mov Disord. 2007;22(11):1678-1679. DOI: 10.1002/mds.21579. 109. Peroza LR, Schaffer LF, De Freitas CM, Leal CQ, Ferrari MC, Duarte MF, Fachinetto R. Alteration of Cytokines Levels in the Striatum of Rats: Possible Participation in Vacuous Chewing Movements Induced by Antipsychotics. Neurochem Res. 2016;41(9):2481-2489. DOI: 10.1007/s11064- 016-1961-6. 110. Naidu PS, Kulkarni SK. Possible involvement of prostaglandins in haloperidol-induced orofacial dyskinesia in rats. Eur J Pharmacol. 2001;430(2-3):295-298. DOI: 10.1016/s0014-2999(01)01385-1. 111. Liu H, Kang Y, Liang J, Li C, Xiu M, Chen D, Yang F, Wang F, Wu G, Haile CN, Kosten TA, Kosten TR, Zhang XY. Lower serum interleukin-2 levels in schizophrenic patients with tardive dyskinesia. Psychiatry Res. 2012;198(2):329-331. DOI: 10.1016/j.psychres.2012.01.002. 112. Tian L, Tan Y, Chen DC, Lv M, Tan S, Jair C Soares JC, Zhang XY. Reduced serum TNF alpha level in chronic schizophrenia patients with or without tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry. 2014;54:259-264. DOI: 10.1016/j.pnpbp.2014.06.012 113. An HM, Tan YL, Shi J, Wang ZR, Soars JC, Wu JQ, Yang FD, Huang XF, Zhang XY. Altered IL-2, IL-6 and IL-8 serum levels in schizophrenia patients with tardive dyskinesia. Schizophr Res. 2015;162(1-3):261-268. DOI: 10.1016/j.schres.2014.12.037. 114. Wang F, Fan H, Sun H, Yang F, Luo Y, Liu H, Kosten TR, Lu L, Zhang XY. Association between TNF-α promoter -308A/G polymorphism and tardive dyskinesia Chinese Han patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37(1):106-110. DOI: 10.1016/j.pnpbp. 2011.12.007 115. Sun H, Wang F, Fan H, Yan Q, Cui K, Yuan W, Zhao F, Zhao L, Yuan J, Yang F, Kosten TR, Zhang XY. The interaction of polymorphisms of IL10 and DBH was associated with general symptoms of PANSS with TD in Chinese Han schizophrenic patients. PLoS One. 2013;8(8):e70963. DOI: 10.1371/journal.pone.0070963. 116. Bošković M, Vovk T, Saje M, Goričar K, Dolžan V, Plesničar BK, Grabnar I. Association of SOD2, GPX1, CAT, and TNF genetic polymorphisms with oxidative stress, neurochemistry, psychopathology, and extrapyramidal symptoms in schizophrenia. Neurochem Res. 2013;38(2):433-442. DOI: 10.1007/s11064-012-0937-4 117. Fond G, Lançon C, Korchia T, Auquier P, Boyer L. The Role of Inflammation in the Treatment of Schizophrenia. Front Psychiatry. 2020;11:160. DOI: 10.3389/fpsyt.2020.00160. 118. Hong J, Bang M. Anti-inflammatory Strategies for Schizophrenia: A Review of Evidence for Therapeutic Applications and Drug Repurposing. Clin Psychopharmacol Neurosci. 2020;18(1):10-24. DOI: 10.9758/cpn.2020.18.1.10. 119. Jensen N, Oliveira JRM. Basal ganglia vulnerability to oxidative stress. Front Neurosci. 2014;8:80. DOI: 10.3389/fnins.2014.00080 120. Crowley JJ, Ashraf-Khorassani M, Castagnoli N Jr, Sullivan PF. Brain levels of the neurotoxic pyridinium metabolite HPP+ and extrapyramidal symptoms in haloperidol-treated mice. Neurotoxicology. 2013;39:153-157. doi: 10.1016/j.neuro.2013.09.005 121. Lepping P, Delieu J, Mellor R, Williams JH, Hudson PR, Hunter-Lavin C. Antipsychotic medication and oxidative cell stress: a systematic review. J Clin Psychiatry. 2011;72(3):273-285. DOI: 10.4088/JCP.09r05268yel 122. Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010;33(6):271–275. DOI: 10.1097/wnf.0b013e3181ffde32 123. Tiwari AK, Deshpande SN, Rao AR, Bhatia T, Lerer B, Nimgaonkar VL, Thelma BK. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms. Schizophr Res. 2005;75(1):21- 26. DOI: 10.1016/j.schres. 2004.12.011 124. Gałecki P, Pietras T, Szemraj J. Manganese superoxide dismutase gene (MnSOD) polimorphism in schizophrenics with tardive dyskinesia from central Poland [in Polish]. Psychiatr Pol. 2006;40(5):937- 948. 125. Lee HJ, Kang SG. Genetics of tardive dyskinesia. Int Rev Neurobiol. 2011;98:231-264.DOI: 10.1016/B978-0-12-381328-2.00010-9 126. Fedorenko OY, Loonen AJM, Lang F, Toshchakova VA, Boyarko EG, Semke AV, Bokhan NA, Govorin NV, Aftanas LI, Ivanova SA. Association study indicates a protective role of phosphatidylinositol-4-phosphate-5-kinase against tardive dyskinesia. Int J Neuropsychopharmacol. 2014; 18 6 doi:10.1093/ijnp/pyu098. 127. Liao DL, Yeh YC, Chen HM, Chen H, Hong CJ, Tsai SJ. Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology. 2001;44(2):95- 98. DOI: 10.1159/000054924